Aaron Fink
Psychiatry · Houston, TXNPI 1619248622
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $24,750 of the $40,769 with a category attached, or 60.7%. Ironshore Pharmaceuticals Inc. accounts for 82.9% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2019 at $35,544 and has fallen 98.1% since, to $688 in 2025. Among psychiatry clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 205 payments — averaging $198.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ironshore Pharmaceuticals Inc.$34K
- Supernus Pharmaceuticals, Inc.$3K
- Alfasigma USA, Inc.$700
- Tris Pharma Inc$448
- Corium, LLC$443
- AbbVie$360
- plus $2K from 15 others
What the payments were for
- Consulting fees$4,63011%
- Speaking & faculty fees$24,75061%
- Travel & lodging$6,01715%
- Food & beverage$5,37213%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ironshore Pharmaceuticals Inc. | 66 | $33,792 |
| Supernus Pharmaceuticals, Inc. | 11 | $3,223 |
| Alfasigma USA, Inc. | 1 | $700 |
| Tris Pharma Inc | 12 | $448 |
| Corium, LLC | 23 | $443 |
| AbbVie(2 entities) | 17 | $360 |
| Otsuka America Pharmaceutical, Inc. | 13 | $318 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $301 |
| Johnson & Johnson | 6 | $289 |
| Sunovion Pharmaceuticals Inc. | 8 | $150 |
| Acadia Pharmaceuticals Inc | 1 | $125 |
| Shire North American Group Inc | 5 | $112 |
| Axsome Therapeutics, Inc. | 2 | $112 |
| Neos Therapeutics, LP | 7 | $102 |
| Lundbeck LLC | 4 | $61 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $57 |
| Teva Pharmaceuticals USA, Inc. | 4 | $54 |
| Vertical Pharmaceuticals, LLC | 2 | $46 |
| Vanda Pharmaceuticals Inc. | 2 | $42 |
| Alkermes, Inc. | 1 | $19 |
| Collegium Pharmaceutical, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Jornay PM 20mg capsules (Bottle of 100)$33,153
- Dyanavel XR$374
- Quillivant$250
- Quillichew ER$250
- SPRAVATO$235
- DAYBUE$125
- VRAYLAR$123
How this compares
$40,769 in reported general payments places this provider in the 95th percentile of 2,238 psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrintellixVortioxetine Hydrobromide | 33 | $18,040 |
| Adzenys Xr-OdtAmphetamine | 14 | $11,655 |
| VyvanseLisdexamfetamine Dimesylate | 21 | $8,214 |
| Lisdexamfetamine Dimesylate | 29 | $5,497 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 27 | $3,470 |
| Quetiapine Fumarate | 38 | $1,868 |
| Bupropion XlBupropion Hcl | 127 | $1,758 |
| Duloxetine Hcl | 35 | $1,564 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 34 | $1,129 |
| Mirtazapine | 50 | $1,070 |
| Clorazepate Dipotassium | 21 | $782 |
| Fluoxetine Hcl | 31 | $678 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 14 | $669 |
| Escitalopram Oxalate | 40 | $656 |
| Aripiprazole | 12 | $511 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $301 | $26,25454 claims |
| Neos Therapeutics, LPAdzenys Xr-Odt | $102 | $11,65514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Houston
- Matthew BramsHouston$1.5M
- Frank ChenHouston$941K
- Alice MaoHouston$850K
- Mazhar KhowajaHouston$843K
- Barry GritzHouston$792K
- Aaron PetersonHouston$700K
- Ayesha RashidHouston$641K
- Lawrence GinsbergHouston$502K
- Kathy FlanaganHouston$443K
- Rayan Al JurdiHouston$359K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.